Inclusion criteria:

          1. Male or female patients ≥ 18 years of age.

          2. ECOG 0, 1, or 2.

          3. Patients with Ph+ CML who have failed treatment in the core protocol.

          4. Diagnosis of chronic myelogenous leukemia with cytogenetic confirmation of
             Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL a review of a
             minimum 20 metaphases is required).

          5. Adequate end organ function as defined by:

               -  Total bilirubin < 1.5 x ULN,

               -  SGOT and SGPT < 2.5 x ULN,

               -  Creatinine < 1.5 x ULN,

               -  Serum amylase and lipase ≤ 1.5 x ULN,

               -  Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.

          6. Patients must have the following laboratory values (≥ LLN (lower limit of normal) or
             corrected to within normal limits with supplements prior to the first dose of study
             medication.):

               -  Potassium ≥ LLN,

               -  Magnesium ≥ LLN,

               -  Phosphorus ≥ LLN,

               -  Total calcium (corrected for serum albumin) ≥ LLN.

        Exclusion criteria:

          1. Previously documented T315I mutations.

          2. Impaired cardiac function including any one of the following:

               -  LVEF < 45% or below the institutional lower limit of the normal range (whichever
                  is higher) as determined by locally read echocardiogram.

               -  Inability to determine the QT interval on ECG.

               -  Complete left bundle branch block.

               -  Use of a ventricular-paced pacemaker.

               -  Congenital long QT syndrome or a known family history of long QT syndrome.

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmias.